Roth J A, Atkinson E N, Fossella F, Komaki R, Bernadette Ryan M, Putnam J B, Lee J S, Dhingra H, De Caro L, Chasen M, Hong W K
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Lung Cancer. 1998 Jul;21(1):1-6. doi: 10.1016/s0169-5002(98)00046-4.
Our previously reported randomized study of patients with untreated, potentially resectable clinical stage IIIA non-small-cell lung cancer found that patients treated with perioperative chemotherapy and surgery had a significant increase in median survival compared to patients treated with surgery alone. We have now re-analyzed the results of the study with a median time from random allocation to analysis for all patients of 82 months. The increase in survival conferred by perioperative chemotherapy was maintained during the period of extended observation.
我们之前报道的一项针对未经治疗、可能可切除的临床 IIIA 期非小细胞肺癌患者的随机研究发现，与单纯接受手术治疗的患者相比，接受围手术期化疗和手术治疗的患者中位生存期显著延长。我们现在对该研究结果进行了重新分析，所有患者从随机分组到分析的中位时间为 82 个月。在延长观察期内，围手术期化疗带来的生存获益得以维持。
